重新审视帕金森病的药物治疗：左旋多巴与多巴胺激动剂
Revisiting the Medical Management of Parkinson's Disease: Levodopa versus Dopamine Agonist.
作者信息
Zhang Jinglin, Tan Louis Chew-Seng
机构信息
Parkinson's Disease and Movement Disorder Center, Department of Neurology, National Neuroscience Institute, Republic of Singapore, USA National Parkinson Foundation International Center of Excellence, Singapore, 11 Jalan Tan Tock Seng, Singapore, 308433.
出版信息
Curr Neuropharmacol. 2016;14(4):356-63. doi: 10.2174/1570159x14666151208114634.
Abstract
The optimal treatment strategy for Parkinson's disease has been debated for decades. The introduction of levodopa (LD) treatment is frequently delayed because of theoretical concerns about its toxicity or the risk of drug-induced motor complications. These concerns have resulted in "LD phobia" with clinicians selecting dopamine agonist (DA) over LD as initial therapy. More recently, a shift in the treatment approach towards initial LD use appears to be occurring. It is therefore necessary to review current evidence for the use of LD and DA. This review discusses the medical management of Parkinson's disease with regards to the use of LD versus DA. Pendulum swings in treatment strategies between LD-first and DA-first therapies should be avoided. A balanced perspective is needed as there is a place for both drugs in the management of PD.
摘要
几十年来，帕金森病的最佳治疗策略一直存在争议。由于对左旋多巴（LD）毒性或药物诱发运动并发症风险的理论担忧，其治疗的引入常常被推迟。这些担忧导致了“LD恐惧症”，临床医生选择多巴胺激动剂（DA）而非LD作为初始治疗。最近，治疗方法似乎正转向初始使用LD。因此，有必要回顾当前使用LD和DA的证据。本综述讨论了帕金森病在使用LD与DA方面的药物治疗。应避免在LD优先和DA优先治疗策略之间摇摆不定。需要一个平衡的观点，因为这两种药物在帕金森病的治疗中都有一席之地。
相似文献
1
Revisiting the Medical Management of Parkinson's Disease: Levodopa versus Dopamine Agonist.重新审视帕金森病的药物治疗：左旋多巴与多巴胺激动剂
Curr Neuropharmacol. 2016;14(4):356-63. doi: 10.2174/1570159x14666151208114634.
2
Initial therapy for Parkinson's disease: levodopa vs. dopamine receptor agonists.帕金森病的初始治疗：左旋多巴与多巴胺受体激动剂
J Neurol. 2002 Sep;249 Suppl 2:II25-9. doi: 10.1007/s00415-002-1205-3.
3
A hospital-based study: risk factors in development of motor complications in 555 Parkinson's patients on levodopa therapy.一项基于医院的研究：555例接受左旋多巴治疗的帕金森病患者发生运动并发症的危险因素。
Clin Neurol Neurosurg. 2006 Dec;108(8):726-32. doi: 10.1016/j.clineuro.2006.02.002. Epub 2006 Mar 27.
4
Risk of Disabling Response Fluctuations and Dyskinesias for Dopamine Agonists Versus Levodopa in Parkinson's Disease.帕金森病中多巴胺激动剂与左旋多巴导致致残性应答波动和运动障碍的风险。
J Parkinsons Dis. 2015;5(4):847-53. doi: 10.3233/JPD-150532.
5
[Dopamine agonist therapy in early Parkinson's disease. A survey of a Cochrane review].[早期帕金森病的多巴胺激动剂治疗。对一项Cochrane系统评价的综述]
Ugeskr Laeger. 2009 Oct 5;171(41):2996-9.
6
An approach to the continuous dopaminergic stimulation in Parkinson's disease.帕金森病持续多巴胺能刺激的一种方法。
Isr Med Assoc J. 2012 Mar;14(3):175-9.
7
Adding a dopamine agonist to preexisting levodopa therapy vs. levodopa therapy alone in advanced Parkinson's disease: a meta analysis.在晚期帕金森病中，在已有左旋多巴治疗基础上加用多巴胺激动剂与单纯左旋多巴治疗的比较：一项荟萃分析。
Int J Clin Pract. 2009 Apr;63(4):613-23. doi: 10.1111/j.1742-1241.2009.02027.x. Epub 2009 Feb 16.
8
Agonists versus levodopa in PD: the thrilla of whitha.帕金森病中激动剂与左旋多巴的比较：一场激烈的较量
Neurology. 2003 Nov 25;61(10):1462; author reply 1462-3. doi: 10.1212/wnl.61.10.1462.
9
Drugs and drug delivery in PD: optimizing control of symptoms with pramipexole prolonged-release.药物与药物递送在 PD 中的应用：用普拉克索控释片优化症状控制。
Eur J Neurol. 2011 Mar;18 Suppl 1:3-10. doi: 10.1111/j.1468-1331.2010.03326.x.
10
The long-acting dopamine receptor agonist cabergoline in early Parkinson's disease: final results of a 5-year, double-blind, levodopa-controlled study.长效多巴胺受体激动剂卡麦角林用于早期帕金森病：一项为期5年的双盲、左旋多巴对照研究的最终结果
CNS Drugs. 2004;18(11):733-46. doi: 10.2165/00023210-200418110-00003.
引用本文的文献
1
Trends in Parkinson's disease medication prescribing patterns in the UK: An interrupted time series analysis (2019-2024).英国帕金森病药物处方模式的趋势：中断时间序列分析（2019 - 2024年）
PLoS One. 2025 May 23;20(5):e0324999. doi: 10.1371/journal.pone.0324999. eCollection 2025.
2
Changes in neurologists' treatment preferences for Parkinson's disease in the Netherlands.荷兰神经科医生对帕金森病治疗偏好的变化。
Clin Park Relat Disord. 2024 Feb 15;10:100241. doi: 10.1016/j.prdoa.2024.100241. eCollection 2024.
3
Drug Permeability: From the Blood-Brain Barrier to the Peripheral Nerve Barriers.药物渗透性：从血脑屏障到外周神经屏障
Adv Ther (Weinh). 2023 Apr;6(4). doi: 10.1002/adtp.202200150. Epub 2023 Jan 18.
4
Dopamine agonist monotherapy utilization in patients with Parkinson's disease.帕金森病患者多巴胺激动剂单药治疗的应用情况
Clin Park Relat Disord. 2022 Dec 17;8:100173. doi: 10.1016/j.prdoa.2022.100173. eCollection 2023.
5
Treatment initiation for parkinson's disease in Australia 2013-2018: a nation-wide study.2013 - 2018年澳大利亚帕金森病的治疗起始情况：一项全国性研究。
BMC Geriatr. 2022 Jun 3;22(1):483. doi: 10.1186/s12877-022-03095-3.
6
Difference in rural and urban Medicare prescription pattern for Parkinson's disease in Hawai'i.夏威夷农村和城市地区帕金森病医疗保险处方模式的差异。
Clin Park Relat Disord. 2022 Apr 22;6:100144. doi: 10.1016/j.prdoa.2022.100144. eCollection 2022.
7
An assessment of Parkinson's disease medication treatment patterns in the Medicaid population.对医疗补助人群中帕金森病药物治疗模式的评估。
Clin Park Relat Disord. 2021 Sep 27;5:100109. doi: 10.1016/j.prdoa.2021.100109. eCollection 2021.
8
The role of neuroimaging in Parkinson's disease.神经影像学在帕金森病中的作用。
J Neurochem. 2021 Nov;159(4):660-689. doi: 10.1111/jnc.15516. Epub 2021 Oct 3.
9
Factors affecting the choice of first-line therapy in Parkinson's disease patients in Wales: A population-based study.威尔士帕金森病患者一线治疗选择的影响因素：一项基于人群的研究。
Saudi Pharm J. 2021 Feb;29(2):206-212. doi: 10.1016/j.jsps.2021.01.004. Epub 2021 Jan 28.
10
Autophagy and Redox Homeostasis in Parkinson's: A Crucial Balancing Act.帕金森病中的自噬与氧化还原稳态：关键的平衡行为
Oxid Med Cell Longev. 2020 Nov 10;2020:8865611. doi: 10.1155/2020/8865611. eCollection 2020.
本文引用的文献
1
EuroInf: a multicenter comparative observational study of apomorphine and levodopa infusion in Parkinson's disease.欧洲信息网络：一项关于阿扑吗啡和左旋多巴输注治疗帕金森病的多中心比较观察性研究。
Mov Disord. 2015 Apr;30(4):510-6. doi: 10.1002/mds.26067. Epub 2014 Nov 10.
2
Initiating dopaminergic treatment in Parkinson's disease.帕金森病的多巴胺能治疗起始
Lancet. 2014 Sep 27;384(9949):1164-6. doi: 10.1016/S0140-6736(14)60962-4. Epub 2014 Jun 11.
3
Long-term effectiveness of dopamine agonists and monoamine oxidase B inhibitors compared with levodopa as initial treatment for Parkinson's disease (PD MED): a large, open-label, pragmatic randomised trial.长效多巴胺受体激动剂和单胺氧化酶 B 抑制剂与左旋多巴作为帕金森病（PD MED）初始治疗的长期疗效比较：一项大型、开放标签、实用随机试验。
Lancet. 2014 Sep 27;384(9949):1196-205. doi: 10.1016/S0140-6736(14)60683-8. Epub 2014 Jun 11.
4
Pharmacological treatment of Parkinson disease: a review.帕金森病的药物治疗：综述。
JAMA. 2014;311(16):1670-83. doi: 10.1001/jama.2014.3654.
5
Factors predictive of the development of levodopa-induced dyskinesia and Wearing-Off in Parkinson's disease.帕金森病中左旋多巴诱发异动症和剂末现象发生发展的预测因素。
Mov Disord. 2014 Mar;29(3):429. doi: 10.1002/mds.25800. Epub 2013 Dec 27.
6
Pathogenesis-targeted, disease-modifying therapies in Parkinson disease.帕金森病中针对发病机制的疾病修饰疗法。
Neurotherapeutics. 2014 Jan;11(1):6-23. doi: 10.1007/s13311-013-0218-1.
7
Factors predictive of the development of Levodopa-induced dyskinesia and wearing-off in Parkinson's disease.帕金森病中左旋多巴诱导的运动障碍和开-关现象发展的预测因素。
Mov Disord. 2013 Jul;28(8):1064-71. doi: 10.1002/mds.25364. Epub 2013 Apr 29.
8
Nonmotor fluctuations in Parkinson disease: severity and correlation with motor complications.帕金森病的非运动波动：严重程度与运动并发症的相关性。
Neurology. 2013 Feb 26;80(9):800-9. doi: 10.1212/WNL.0b013e318285c0ed. Epub 2013 Jan 30.
9
Summary of the recommendations of the EFNS/MDS-ES review on therapeutic management of Parkinson's disease.欧洲神经病学学会/运动障碍学会治疗帕金森病管理审查建议摘要。
Eur J Neurol. 2013 Jan;20(1):5-15. doi: 10.1111/j.1468-1331.2012.03866.x.
10
Moving from continuous dopaminergic stimulation to continuous drug delivery in the treatment of Parkinson's disease.从连续多巴胺刺激到帕金森病治疗中的持续药物输送的转变。
Eur J Neurol. 2012 Dec;19(12):1502-8. doi: 10.1111/j.1468-1331.2011.03593.x. Epub 2012 Jan 4.
Zotero 插件